When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data

MLA

Rebecca N Jerome, et al. “When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.” ASSAY and Drug Development Technologies, vol. 15, Dec. 2017, pp. 354–61. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....120a19ffddaa2e29b51daa0770bcc6b8&authtype=sso&custid=ns315887.

APA

Rebecca N Jerome, Robert R. Lavieri, Gordon R. Bernard, Helen M. Naylor, Somsundaram N. Chettiar, Kenneth J. Holroyd, Nicole M. Zaleski, Leslie J. Crofford, Andrea J. Pruijssers, David A. Edwards, Jana K. Shirey-Rice, Jill M. Pulley, Laura L. Dugan, David M. Aronoff, & Colleen M. Niswender. (2017). When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data. ASSAY and Drug Development Technologies, 15, 354–361.

Chicago

Rebecca N Jerome, Robert R. Lavieri, Gordon R. Bernard, Helen M. Naylor, Somsundaram N. Chettiar, Kenneth J. Holroyd, Nicole M. Zaleski, et al. 2017. “When Enough Is Enough: Decision Criteria for Moving a Known Drug into Clinical Testing for a New Indication in the Absence of Preclinical Efficacy Data.” ASSAY and Drug Development Technologies 15 (December): 354–61. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....120a19ffddaa2e29b51daa0770bcc6b8&authtype=sso&custid=ns315887.